A Phase 4 interventional study of Denosumab and Zoledronic Acid in Sarcopenia and Osteoporosis, sponsored by Nami Safai Haeri. Completed at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Nami Safai Haeri · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Sarcopenia with a site in United States — 36 open to participants now, 46 under way, 1 of them phase 3. Sarcopenia · United States.
Among the 187 studies in Sarcopenia with a site in United States, this one is the 110th largest by enrollment of the 146 interventional ones that give a count, is one of 15 that started in 2023, is one of 5 in phase 4, and was the 151st registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →36 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
Kennesaw State University · Sites in United States
Ages 65–85 · Healthy volunteers
Health Discovery Labs · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 65 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 3 · Phase 4 5
First in 1995; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 40 across the 146 interventional studies, 70 across the 40 observational. Of the 127 that completed or were terminated, 44 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 187 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nami Safai Haeri as lead sponsor.
Nami Safai Haeri has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
17 of the studies in Sarcopenia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT07421648SynchroHealth LLCBandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4 | 2026-12 |
| NCT06722508University of California, DavisExercise and Nutritional Prehabilitation for Head and Neck Cancer Patients | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06628349Texas A&M UniversityPrandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 187 studies in Sarcopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ambulatory adults age ≥65 years including those using assistive devices to maximize generalizability, if they have criteria for treating osteoporosis including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zoledronic acid 5 mg IV infusion at month 0, with placebo subcutaneous injections at months 0 and 6. Open-label zoledronic acid 5 mg IV at month 12.
Drug: Zoledronic Acid · Other: Denosumab Placebo
Denosumab 60 mg subcutaneous injection at months 0 and 6, with placebo IV infusion at month 0. Open-label zoledronic acid 5 mg IV at month 12.
Drug: Denosumab · Other: Zoledronic Acid Placebo
Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
Change From Baseline in Urinary D3-creatinine Enrichment (D3-creatine Dilution)
Muscle creatine pool size was estimated by D3-creatine dilution. Participants took a single 30 mg oral dose of deuterium-labeled creatine at baseline and 12 months, with a fasting morning urine sample collected approximately 72 hours later. Urinary D3-creatinine and total creatinine were measured by liquid chromatography-mass spectrometry. Enrichment is the " mol/mol ratio" of D3-creatinine to total creatinine in the same molar units, a dimensionless value from 0 to 1 (baseline values here were approximately 0.03, or 3%). Because about 95% of body creatine is in skeletal muscle, higher enrichment reflects less tracer dilution in a smaller pool and therefore less muscle mass. Reported values are the change (Month 12 minus Baseline), so a positive value is consistent with decreased muscle mass. Enrichment is reported rather than derived muscle mass because derived values showed high intra-individual variability.
Time frame: Baseline vs Month 12
Percentage Change From Baseline in Bone Mineral Density (BMD)
BMD is measured by a DXA scan system and a higher BMD is correlated with lower fracture risk
Time frame: Baseline vs Month 12
Change From Baseline in Appendicular Lean Mass.
Appendicular lean mass was measured by whole-body dual-energy X-ray absorptiometry and defined as the sum of lean soft tissue mass of both arms and both legs divided by height in meters squared "in kg/m²", excluding bone mineral content and fat mass. Values reported are the change (Month 12 minus Baseline) in appendicular lean mass index; a negative value indicates a decrease.
Time frame: Baseline vs Month 12
Change From Baseline in Grip Strength
Grip strength is measure of muscle strength and will be measured by a standard hand dynamometer
Time frame: Baseline vs Month 12
Change From Baseline in 4-Meter Walk Time (Gait Speed)
Gait speed is a measure of muscle function and will be measured by standard 4 meter gait speed test
Time frame: Baseline vs Month 12
Change From Baseline in Rectus Femoris Muscle Thickness (cm)
This variable will be measured by ultrasound
Time frame: Baseline vs Month 12
Change From Baseline in Rectus Femoris Muscle Cross-sectional Surface Area (cm²)
This variable will be measured by ultrasound
Time frame: Baseline vs Month 12
CTX Changes
Marker of bone resorption
Time frame: Baseline vs Month 12
| Milestone | Denosumab | Zoledronic Acid |
|---|---|---|
| Started | 10 | 10 |
| Completed | 9 | 10 |
| Not completed | 1 | 0 |
Muscle creatine pool size was estimated by D3-creatine dilution. Participants took a single 30 mg oral dose of deuterium-labeled creatine at baseline and 12 months, with a fasting morning urine sample collected approximately 72 hours later. Urinary D3-creatinine and total creatinine were measured by liquid chromatography-mass spectrometry. Enrichment is the " mol/mol ratio" of D3-creatinine to total creatinine in the same molar units, a dimensionless value from 0 to 1 (baseline values here were approximately 0.03, or 3%). Because about 95% of body creatine is in skeletal muscle, higher enrichment reflects less tracer dilution in a smaller pool and therefore less muscle mass. Reported values are the change (Month 12 minus Baseline), so a positive value is consistent with decreased muscle mass. Enrichment is reported rather than derived muscle mass because derived values showed high intra-individual variability.
| Ratio | Denosumab | Zoledronic Acid |
|---|---|---|
| Change From Baseline in Urinary D3-creatinine Enrichment (D3-creatine Dilution) | 0.005 ± 0.006 | 0.001 ± 0.006 |
BMD is measured by a DXA scan system and a higher BMD is correlated with lower fracture risk
| percentage change | Denosumab | Zoledronic Acid |
|---|---|---|
| Lumbar Spine | 5.2 ± 3.2 | 4.9 ± 2.5 |
| Total Hip | 3.2 ± 1.9 | 1.4 ± 1.2 |
| Femoral Neck | 3.5 ± 3.5 | 0.2 ± 2.9 |
Appendicular lean mass was measured by whole-body dual-energy X-ray absorptiometry and defined as the sum of lean soft tissue mass of both arms and both legs divided by height in meters squared "in kg/m²", excluding bone mineral content and fat mass. Values reported are the change (Month 12 minus Baseline) in appendicular lean mass index; a negative value indicates a decrease.
| kg/m² | Denosumab | Zoledronic Acid |
|---|---|---|
| Change From Baseline in Appendicular Lean Mass. | -0.049 ± 0.203 | -0.044 ± 0.282 |
Grip strength is measure of muscle strength and will be measured by a standard hand dynamometer
| kg | Denosumab | Zoledronic Acid |
|---|---|---|
| Change From Baseline in Grip Strength | 1.39 ± 1.88 | 3.08 ± 3.00 |
Gait speed is a measure of muscle function and will be measured by standard 4 meter gait speed test
| s | Denosumab | Zoledronic Acid |
|---|---|---|
| Change From Baseline in 4-Meter Walk Time (Gait Speed) | -0.46 ± 0.58 | -0.28 ± 0.60 |
This variable will be measured by ultrasound
| cm | Denosumab | Zoledronic Acid |
|---|---|---|
| Change From Baseline in Rectus Femoris Muscle Thickness (cm) | 0.02 ± 0.11 | 0.02 ± 0.12 |
This variable will be measured by ultrasound
| cm² | Denosumab | Zoledronic Acid |
|---|---|---|
| Change From Baseline in Rectus Femoris Muscle Cross-sectional Surface Area (cm²) | 0.15 ± 0.39 | 0.14 ± 0.18 |
Marker of bone resorption
| pg/ml | Denosumab | Zoledronic Acid |
|---|---|---|
| CTX Changes | -326.1 ± 128.8 | -266.6 ± 223.6 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Denosumab | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
All randomized participants.
| Age, Categorical(Participants) | Denosumab | Zoledronic Acid | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 10 | 10 | 20 |
| Sex: Female, Male(Participants) | Denosumab | Zoledronic Acid | Total |
|---|---|---|---|
| Female | 10 | 10 | 20 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Denosumab | Zoledronic Acid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 9 | 18 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Denosumab | Zoledronic Acid | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
| Grip Strength(Kg) | Denosumab | Zoledronic Acid | Total |
|---|---|---|---|
| Mean | 17.2 ± 3.7 | 18.3 ± 4.3 | 17.75 ± 3.99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Jan 2026, 34 months.
Results were first posted in Oct 2026, 9 months after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Denosumab · Zoledronic Acid